“We need to convince senior managers in local countries to invest appropriately in market access.” PAREXEL…
You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
Real world evidence tailored to meet the specific needs of a range of reimbursement agencies is essential to help strengthen the value message in your new drug submissions.
There are many different Health Technology Assessment agencies around the world who all have very different standards for granting approvals, each placing differing levels of emphasis on different factors. These differences can sometimes reduce the return a company would usually expect to receive.
To avoid this, there are two important steps pharmaceutical development companies can take:
1. Assess of the need for the drug in accordance with the requirements of each individual agency
2. Support key messages by gathering the evidence you will need.
A successful product launch demands intense early engagement with an array of stakeholders beyond regulators and payers.…
Pricing & Reimbursement
Regulatory & Payer Submissions